Protective effect of centrally-injected glucagon-like peptide-1 on reserpine-induced gastric mucosal lesions in rat: Possible mechanisms

Turkish Journal of Gastroenterology

Volumn 17, Issue 1, 2006, Pages 1-6

  Isbil Buyukcoskun, Naciye ^a   Güleç, Güldal ^a   Özlük, Kasim ^a  

^a ULUDAG UNIVERSITY   (Turkey)

Author keywords

Cholinergic system; Glucagon like peptide 1; Intracerebroventricular; Nitric oxide; Rat; Somatostatin; Stomach; Sympathetic system

Indexed keywords

ATROPINE; GLUCAGON LIKE PEPTIDE 1; MECAMYLAMINE; MERCAPTAMINE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; RESERPINE; SOMATOSTATIN; YOHIMBINE;

ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC TRANSMISSION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; NONHUMAN; RAT; STOMACH MUCOSA LESION; STOMACH PROTECTION;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; FEMALE; GLUCAGON-LIKE PEPTIDE 1; NITRIC OXIDE; RATS; RATS, SPRAGUE-DAWLEY; RESERPINE; SOMATOSTATIN; STOMACH ULCER; SYMPATHETIC NERVOUS SYSTEM;

EID: 34047202994     PISSN: 13004948     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Nagy L, Mozsik G, Fiegler M, et al. Role of the functional state of the gastric mucosa in relation to development of epinephrine effects on rat stomach. In: Mozsik G, Hanninen O, Javar T, eds. Advances in Physiological Sciences. Budapest: Pergamon Press, 1981; 89-100.
2. Sandor V, Cuparencu B. Analysis of the mechanism of the protective activity of some sympathomimetic amines in experimental ulcers. Pharmacology 1977; 15: 208-17.
3. Yamaguchi I, Hiroi J, Fuke H, et al. Mechanism of gastric secretagogue effect of reserpine in rat. J Pharmacol Exp Ther 1978; 205: 710-6.
4. Kagoshima M, Suguro N. Gastric movements and reserpine-induced ulcers in rats. Nippon Yakurigaku Zasshi 1982; 80: 231-8.
5. Clementi G, Amico-Roxas M, Caruso A, et al. Protective effects of calcitonin gene-related peptide in different experimental models of gastric ulcers. Eur J Pharmacol 1993; 238: 101-4.
6. Clementi G, Caruso A, Cutuli VMC, et al. Effects of centrally or peripherally injected adrenomedullin on reserpine-induced gastric lesions. Eur J Pharmacol 1998; 360: 51-4.
7. Guidobono F, Pagani F, Ticozzi C, et al. Protection by amylin of gastric erosions induced by indomethacin or ethanol in rats. Br J Pharmacol 1997; 120: 581-6.
8. Nakane T, Kanie N, Audhya T, et al. The effects of centrally administered neuropeptides on the development of gastric lesions in the rat. Life Sci 1985; 36(12): 1197-203.
9. Sibilia V, Rindi G, Pagani F, et al. Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 2003; 144(1): 353-9.
10. Kieffer TJ, Habener JF. The glucagon-like peptides. Endow Rev 1999; 20(6): 876-913.
11. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122: 531-44.
12. Elliot RM, Morgan LM, Tredger A, et al. Glucagon-like peptide-1 (7-36) amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h patterns. J Endocrinol 1993; 138: 159-66.
13. Fehmann HC, Habener JF. Insulinotropic glucagon-like peptide-1 (7-37)/(7-36) amide: a new incretin hormone. Trends Endocrinol Metab 1992; 3: 158-63.
14. Sjoholm A, Efendic S. Neurohormonal regulation of the insulin stimulus-secretion coupling in pancreatic islets. Exp Clin Endocrinol Diabetes 2001; 109(2): S109-21.
15. Schirra J, Kuwert P, Wank U, et al. Differential effects of subcutaneous GLP-1 on gastric emptying, antroduodenal motility, and pancreatic function in men. Proc Assoc Am Physicians 1997; 109(1): 84-97.
16. Wettergren A, Wojdemann M, Hoist JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998; 275(38): G984-92.
17. Delgado-Aros S, Kim DY, Burton DD, et al. Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans. Am J Physiol 2002; 282: G424-31.
18. Imeryuz N, Yegen BC, Bozkurt A, et al. Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 1997; 273(4): G920-7.
19. Tolessa T, Naslund E, Hellström M. The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway. Regul Pept 2001; 98: 33-40.
20. Wettergren A, Wojdemann M, Meisner S, et al. The inhibitor effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 1997; 40: 597-601.
21. Isbil-Buyukcoskun N, Gulec G. Effects of centrally injected GLP-1 in various experimental models of gastric mucosal damage. Peptides 2004; 25: 1179-83.
22. Hierlihy LE, Wallace JL, Ferguson AV. Role of gastric acid secretion and blood flow in the development of vagal stimulation induced gastric mucosal damage. Can J Physiol Pharmacol 1993; 71: 829-34.
23. Holzer P. Neural emergency system in the stomach. Gastroenterology 1998; 114: 823-39.
24. Gyires K, Mullner K, Furst S, et al. Alpha-2 adrenergic and opioid receptor-mediated gastroprotection. J Physiol Paris 2000; 94: 117-21.
25. Samini M, Mohaghegh M, Hasanzadeh F, et al. Anti-ulcer effect of bromocriptine on indomethacin-induced gastric damage in rats. Pharm Pharmacol Commun 2000; 6: 411-3.
26. Rossowski WJ, Cheng BL, Jiang NY, et al. Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue. Br J Pharmacol 1998; 125: 1081-7.
27. Berg A, Redeen S, Ericson AC, et al. Nitric oxide - an endogenous inhibitor of gastric acid secretion in isolated human gastric glands. BMC Gastroenterol 2004; 4(16): 2-9.
28. Hasebe K, Horie S, Yano S, et al. Stimulatory effects of nitric oxide donors on histamine release in isolated rat gastric mucosal cells. Biol Pharm Bull 2003; 26(7): 950-3.
29. Elliott SN, Wallace JL. Nitric oxide: a regulator of mucosal defense and injury. J Gastroenterol 1998; 33: 792-803.
30. Lau HK, Ogle CW. The influence of cimetidine, a histamine H2-receptor antagonist, on the gastric effects of reserpine in rats. Eur J Pharmacol 1981; 70: 139-48.
31. Isbil-Buyukcoskun N, Gulec G. Investigation of the mechanisms involved in the central effects of glucagon-like peptide-1 on ethanol-induced gastric mucosal lesions. Regul Pept 2005; 128: 57-62.
32. Wettergren A. Glucagon-like peptide-1. Gastrointestinal function and possible mechanism of action. Dan Med Bull 2001; 48(1): 19-28.
33. Cheng HC, Gleason EM, Nathan AB, et al. Effects of clonidine on gastric acid secretion in the rat. J Pharmacol Exp Ther 1981; 217: 121-6.
34. Eissele R, Koop H, Arnold R. Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand J Gastroenterol 1990; 25: 449-54.
35. Orskov C, Hoist JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 1988; 123(4): 2009-13.
36. Wettergren A, Petersen H, Orskov J, et al. Glucagon-like peptide-1 (7-36) amide and peptide YY from L-cell of the ileal mucosa are potent inhibitors of vagally induced gastric acid secretion in man. Scand J Gastroenterol 1994; 29: 501-5.
37. Ancha H, Ojeas H, Tedesco D, et al. Somatostatin-induced gastric protection against ethanol: involvement of nitric oxide and effects on gastric mucosal blood flow. Regul Pept 2003; 110: 107-13.
38. Golpon HA, Puechner A, Welte T, et al. Vasorelaxant effect of glucagon-like peptide-(7-36) amide and amylin on the pulmonary circulation of the rat. Regul Pept 2001; 102: 81-6.
39. Richter G, Feddersen O, Wagner U, et al. GLP-1 stimulates secretion of macromolecules from airways and relaxes pulmonary artery. Am J Physiol 1993; 265: L374-81.
40. Nyström T, Gonon AT, Sjöholm A, et al. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept 2005; 125: 173-7.
41. Bruck H, Gossl M, Spitthover R, et al. The nitric oxide synthase inhibitor L-NMMA potentiates noradrenaline-induced vasoconstriction: effects of the alpha2-receptor antagonist yohimbine. J Hypertens 2001; 19(5): 907-11.